CEBPA and neoplasm: Interestingly, Plummer et al. report that the combination of MTL-CEBPA and an immune-checkpoint inhibitor (ICI; pembrolizumab) convert immunologically “cold” tumors into “hot” (inflamed) tumor microenvironments by inducing the differentiation of progenitor monocytes into immunoreactive HLA-DR+ myeloid cells that recruit cytotoxic T cell to the tumor site.56